Advertisement

The T cell as a therapeutic target

  • Ivan G. Otterness
  • Marcia L. Bliven
Chapter
Part of the Inflammation and Drug Therapy Series book series (IDTH, volume 3)

Abstract

There is a constellation of diseases whose pathology is a direct consequence of the immune response. Since there has been a failure to identify either an infectious aetiology or a pathognomonic immune abnormality, these diseases are characterized as being autoimmune. Rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis and multiple sclerosis are all well-known examples. An important therapeutic approach to these diseases is the selective inhibition of immune activity.

Keywords

Myelin Basic Protein Bullous Pemphigoid Adjuvant Arthritis Immune Response Gene Rheumatoid Arth 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Meuer, SC, Acuto, O et al. (1984). The human T-cell receptor. Annu Rev Immunol, 2, 23–50PubMedCrossRefGoogle Scholar
  2. 2.
    Brenner, MB, McLean, J, Dialynas, DP et al. (1986). Identification of a putative second T-cell receptor. Nature, 322, 145–149PubMedCrossRefGoogle Scholar
  3. 3.
    Koning, F, Kruisbeek, AM, Maloy, WL et al. (1988). T Cell receptor gamma/delta chain diversity. J Exp Med, 167, 676–681PubMedCrossRefGoogle Scholar
  4. 4.
    Babbitt, BP, Allen, PM, Matsueda, G et al. (1985). Binding of immunogenic peptides to Ia histocompatibility molecules. Nature, 317, 359–361PubMedCrossRefGoogle Scholar
  5. 5.
    Buus, S, Sette, A, Colon, SM et al. (1987). The relationship between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science, 235, 1353–1358PubMedCrossRefGoogle Scholar
  6. 6.
    Gregerson, PK, Silver, J and Winchester, RJ (1987). The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum, 30, 1205–1213CrossRefGoogle Scholar
  7. 7.
    Christadoss, P, Lindstrom, JM, Melvoid, R and Talal, N (1985). Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics, 21, 33–38PubMedCrossRefGoogle Scholar
  8. 8.
    Rivas, A, Takada, S, Koide, J et al. (1988). CD4 molecules are associated with the antigen receptor complex on activated but not resting T cells. J Immunol, 140, 2912–2918PubMedGoogle Scholar
  9. 9.
    Campbell, IL, Oxbrow, L, Koulmanda, M and Harrison, LC (1988).IFN-γ induces islet cell MHC antigens and enhances autoimmune, streptozotocin-induced diabetes in the mouse. J Immunol, 140, 1111–1116PubMedGoogle Scholar
  10. 10.
    McDonald, AH and Swanborg, RH (1988). Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J Immunol, 140, 1132–1118PubMedGoogle Scholar
  11. 11.
    Mosmann, TR and Coffman, RL (1987). Two types of mouse helper T-cell clones. Implications for immune regulation. Immunol Today, 8, 223–227CrossRefGoogle Scholar
  12. 12.
    Janeway, CA, Jr, Carding, S, Jones, B et al. (1987). CD4+ T cells: specificity and function. Immunol Rev, 101, 39–80CrossRefGoogle Scholar
  13. 13.
    Arthur, RP and Mason, D (1986). T cells that help B cell response to soluble antigen are distinguishable from those producing interleukin 2 on mitogenic or allogeneic stimulation. J Exp Med, 163, 774–786PubMedCrossRefGoogle Scholar
  14. 14.
    Reinherz, EL, Morimoto, C et al. (1982). Heterogeneity of human T4+ inducer T cells defined by a monoclonal antibody that delineates two functional subpopulations. J Immunol, 128, 463–468PubMedGoogle Scholar
  15. 15.
    Greenbaum, LA, Horowitz, JB, Wood, A et al. (1988). Autocrine growth of CD4+ T cells. Differential effects of IL-1 on helper and inflammatory T cells. J Immunol, 140, 1555–1560PubMedGoogle Scholar
  16. 16.
    Trenn, G, Takayama, H, Hu-Li, J et al. (1988). B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes. J Immunol, 140, 1101–1106PubMedGoogle Scholar
  17. 17.
    Duke, O, Panayi, GS, Janossy, G and Poulter, LW (1982). An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol, 49, 22–30PubMedGoogle Scholar
  18. 18.
    Klareskog, L, Forsum, U, Wigren, A and Wigzell, H (1982). Relationships between HLA-DR-expressing cells and T lymphocytes of different subsets in rheumatoid synovial tissue. Scand J Immunol, 15, 501–507CrossRefGoogle Scholar
  19. 19.
    Young, CL, Adamson, III, TC, Vaughan, JH and Fox, RI (1984). Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum, 27, 32–39PubMedCrossRefGoogle Scholar
  20. 20.
    Rose, LM, Ginsberg, AH, Rothstein, TL et al. (1985). Selective loss of a subset of T helper cells in active multiple sclerosis. Proc Natl Acad Sci USA, 82, 7389–7393PubMedCrossRefGoogle Scholar
  21. 21.
    Sato, K, Miyasaka, N, Yamaoka, K et al. (1987). Quantitative defect of CD4+2H4 + cells in systemic lupus erythematosus and Sjögren’s syndrome. Arthritis Rheum, 30, 1407–1411PubMedCrossRefGoogle Scholar
  22. 22.
    Morimoto, C, Reinherz, EL, Borel, Y et al. (1981). Autoantibody to an immunoregulatory inducer population in patients with juvenile rheumatoid arthritis. J Clin Invest, 67, 753–761PubMedCrossRefGoogle Scholar
  23. 23.
    Emery, P, Gentry, KC, MacKay, IR et al. (1987). Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis. Arthritis Rheum, 30, 849–856PubMedCrossRefGoogle Scholar
  24. 24.
    Lasky, HP, Bauer, K and Pope, RM (1988). Increased helper inducer and decreased suppressor inducer phenotypes in the rheumatoid joint. Arthritis Rheum, 31, 52–59PubMedCrossRefGoogle Scholar
  25. 25.
    Greiner, DL, Handler, ES, Nakano, K et al. (1986). Absence of the RT-6 T cell subset in diabetes-prone BB/W rats. J Immunol, 136, 148–151PubMedGoogle Scholar
  26. 26.
    Greiner, DL, Mordes, JP, Handler, ES et al. (1987). Depletion of RT6.1+ T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats. J Exp Med, 166, 461–475PubMedCrossRefGoogle Scholar
  27. 27.
    Holmdahl, R, Jonsson, R, Larsson, P and Klareskog, L (1988). Early appearance of activated CD4+ T lymphocytes and class II antigen-expressing cells in joints of DBA/1 mice immunized with type II collagen. Lab Invest, 58, 53–60PubMedGoogle Scholar
  28. 28.
    Holmdahl, R, Rubin, K, Klareskog, L et al. (1985). Appearance of different lymphoid cells in synovial tissue and peripheral blood during the course of collagen II-induced arthritis in rats. Scand J Immunol, 21, 197–204PubMedCrossRefGoogle Scholar
  29. 29.
    Klareskog, L, Holmdahl, R, Larsson, E and Wigzell, H (1983). Role of T lymphocytes in collagen II induced arthritis in rats. Clin Exp Immunol, 51, 117–125PubMedGoogle Scholar
  30. 30.
    Sriram, S, Solomon, D, Rouse, RV and Steinman, L (1982). Identification of T cell subsets and B lymphocytes in EAE lesions. J Immunol, 129, 1649–1651PubMedGoogle Scholar
  31. 31.
    Whittum, J, Goldschneider, I, Greiner, D and Zurier, R (1985). Developmental abnormalities of terminal deoxynucleotidyl transferase positive bone marrow cells and thymocytes in New Zealand mice: Effects of prostaglandin E1. J Immunol, 135, 272–280PubMedGoogle Scholar
  32. 32.
    Ridge, SC, Zabriske, JB, Oronsky, AL and Kerwar, SS (1985). Streptococcal cell wall arthritis: studies with nude (athymic) inbred Lewis rats. Cell Immunol, 96, 231–234PubMedCrossRefGoogle Scholar
  33. 33.
    Allen, JB, Malone, DG, Wahl, SM et al. (1985). Role of the thymus in streptococcal cell wall-induced arthritis and hepatic granuloma formation: comparative studies of pathology and cell wall distribution in athymic and euthymic rats. J Clin Invest, 76, 1042–1056PubMedCrossRefGoogle Scholar
  34. 34.
    Yocum, DE, Allen, JB, Wahl, SM et al. (1986). Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. Arthritis Rheum, 29, 262–273PubMedCrossRefGoogle Scholar
  35. 35.
    Holoshitz, J, Naparstek, Y, Ben Nun, A and Cohen, IR (1983). Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Science, 219, 56–58PubMedCrossRefGoogle Scholar
  36. 36.
    van Eden, W, Holoshitz, J, Nevo, Z et al. (1985). Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci USA, 82, 5117–5120PubMedCrossRefGoogle Scholar
  37. 37.
    Trentham, DE, Dynesius, RA and David, JR (1978). Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest, 62, 359–366PubMedCrossRefGoogle Scholar
  38. 38.
    Holmdahl, R, Klareskog, L, Rubin, K et al. (1985). T lymphocytes in collagen type II arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol, 22, 295–306PubMedCrossRefGoogle Scholar
  39. 39.
    Seki, N, Sudo, Y, Yoshioka, T et al. (1988). Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J Immunol, 140, 1477–1484PubMedGoogle Scholar
  40. 40.
    Romball, CG and Weigle, WO (1987). Transfer of experimental autoimmune thyroiditis with T cell clones. J Immunol, 138, 1092–1098PubMedGoogle Scholar
  41. 41.
    Pettinelli, CE and McFarlin, DE (1981). Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vivo activation of lymph node cells by myelin basic protein: requirement for Lyt l+2- T lymphocytes. J Immunol, 127, 1420–1423PubMedGoogle Scholar
  42. 42.
    Ben-Nun, A, Wekerle, H and Cohen, IR (1981). The rapid isolation of clonable antigen specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol, 11, 195–199PubMedCrossRefGoogle Scholar
  43. 43.
    Zamvil, S, Nelson, P, Trotter, J et al. (1985). T cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature, 317, 355–358PubMedCrossRefGoogle Scholar
  44. 44.
    Pelletier, L, Pasquier, R, Rossert, J et al. (1988). Autoreactive T cells in mercury-induced autoimmunity. Ability to induce the autoimmune disease. J Immunol, 140, 750–754PubMedGoogle Scholar
  45. 45.
    Helfgott, SM, Kieval, RI, Breedveld, FC et al. (1988). Detection of arthritogenic factor in adjuvant arthritis. J Immunol, 140, 1838–1843PubMedGoogle Scholar
  46. 46.
    Watanabe, R, Wege, H and ter Meulen, V (1983). Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis. Nature, 305, 150–153PubMedCrossRefGoogle Scholar
  47. 47.
    Neu, N, Rose, NR, Beisel, KW et al. (1987). Cardiac myosin induced myocarditis in genetically predisposed mice. J Immunol, 139, 3630–3636PubMedGoogle Scholar
  48. 48.
    Schluesener, HJ, Sobel, RA, Linington, C and Weiner, HL (1987). A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol, 139, 4016–4021PubMedGoogle Scholar
  49. 49.
    Wofsy, D, Ledbetter, JA, Hendler, PL and Seaman, WE (1985). Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol, 134, 852–857PubMedGoogle Scholar
  50. 50.
    Wofsy, D (1986). Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J Immunol, 136, 4554–4560PubMedGoogle Scholar
  51. 51.
    Ranges, GE, Sriram, S and Cooper, SM (1985). Prevention of type II collagen arthritis by in vivo treatment with anti-L3T4. J Exp Med, 162, 1105–1110PubMedCrossRefGoogle Scholar
  52. 52.
    Brostoff, SW and Mason, DW (1984). Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol, 133, 1938–1942PubMedGoogle Scholar
  53. 53.
    Waldor, MW, Sririam, S, Hardy, R et al. (1985). Reversal of experimental allergic encephalomyelitis with a monoclonal antibody to a T cell subset marker. Science, 227, 415–417PubMedCrossRefGoogle Scholar
  54. 54.
    Sriram, S and Roberts, CA (1986). Treatment of established chronic relapsing experimental allergic encephalitis with anti-L3T4 antibodies. J Immunol, 136, 4464–4469PubMedGoogle Scholar
  55. 55.
    Christadoss, P and Dauphinee, MJ (1986). Immunotherapy for myasthenia gravis: a murine model. J Immunol, 136, 2437–2440PubMedGoogle Scholar
  56. 56.
    Wang, Y, Hao, L, Gill, RG and Lafferty, KJ (1987). Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes, 36, 535–538PubMedCrossRefGoogle Scholar
  57. 57.
    Wofsy, D and Seaman, WE (1985). Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med, 161, 378–391PubMedCrossRefGoogle Scholar
  58. 58.
    Bank, I and Chess, L (1985). Perturbations of the T4 molecule transmits a negative signal to T cells. J Exp Med, 162, 1294–1303PubMedCrossRefGoogle Scholar
  59. 59.
    Tite, JP, Sloan, A and Janeway, Jr, CA (1986). The role of L3T4 in T cell activation: L3T4 may be both an Ia-binding protein and a receptor that transduces a negative signal. J Mol Cell Immunol, 2, 179–190PubMedGoogle Scholar
  60. 60.
    Seaman, WE and Wofsy, D (1988). Selective manipulation of the immune response in vivo by monoclonal antibodies. Annu Rev Med, 39, 231–241PubMedCrossRefGoogle Scholar
  61. 61.
    Waldor, MK, Mitchell, D, Kipps, TJ et al. (1987). Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody. J Immunol, 139, 3660–3664PubMedGoogle Scholar
  62. 62.
    Brostoff, SW and White, TM (1986). Treatment of clinical experimental allergic encephalitis in the rat with monoclonal antibody. J Neuroimmunol, 13, 233–240PubMedCrossRefGoogle Scholar
  63. 63.
    Carteron, NL, Wofsy, D and Seaman, WE (1988). Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol, 140, 713–716PubMedGoogle Scholar
  64. 64.
    Rodriguez, M and Sririam, S (1988). Successful therapy of Theiler’s virus-induced demyelination (DA strain) with monoclonal anti-Lyt-2 antibody. J Immunol, 140, 2950–2955PubMedGoogle Scholar
  65. 65.
    Steinman, L, Rosenbaum, JT, Sriram, S and McDevitt, HO (1981). In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci USA, 78, 7111–7114PubMedCrossRefGoogle Scholar
  66. 66.
    Sriram, S and Steinman, L (1983). Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J Exp Med, 158, 1362–1369PubMedCrossRefGoogle Scholar
  67. 67.
    Perry, LL and Green MI (1982). Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies. J Exp Med, 156, 480–491PubMedCrossRefGoogle Scholar
  68. 68.
    Steinman, L, Solomon, D, Lim, M et al. (1983). Prevention of experimental allergic encephalitis with in vivo administration of anti I-A antibody: decreased accumulation of radiolabelled lymph node cells in the central nervous system. J Neuroimmunol, 5, 91–97PubMedCrossRefGoogle Scholar
  69. 69.
    Sriram, S, Topham, DJ and Carroll, L (1987). Haplotype-specific suppression of experimental allergic encephalomyelitis with anti-IA antibodies. J Immunol, 139,1485–1489PubMedGoogle Scholar
  70. 70.
    Adelman, NE, Watling, D and McDevitt, HO (1983). Treatment of NZB/W F1 disease with anti-I-A monoclonal antibodies. J Exp Med, 158, 1350–1355PubMedCrossRefGoogle Scholar
  71. 71.
    Rosenbaum, JT, Adelman, NE and McDevitt, HO (1981). In vivo effects of antibodies to immune response gene products. I. Haplotype specific suppression of humoral immune responses with a monoclonal anti-I-A. J Exp Med, 154, 1694–1702PubMedCrossRefGoogle Scholar
  72. 72.
    Vladutiu, AO and Steinman, L (1987). Inhibition of autoimmune thyroiditis in mice by anti-I-A antibodies. Ceil Immunol, 109, 169–180CrossRefGoogle Scholar
  73. 73.
    Wooley, PH, Luthra, HS, Lafuse, WP et al. (1985). Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera. J Immunol, 134, 2366–2374PubMedGoogle Scholar
  74. 74.
    Waldor, MK, Sriram, S, McDevitt, HO and Steinman, L (1983). In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci USA, 80, 2713–2717PubMedCrossRefGoogle Scholar
  75. 75.
    Ben-Nun, A, Wekerle, H and Cohen, IR (1981). Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein. Nature, 292, 60–63PubMedCrossRefGoogle Scholar
  76. 76.
    Ellerman, KE, Powers, JM and Brostoff, SW (1988). A suppressor T-lymphocyte cell line for autoimmune encephalomyelitis. Nature, 331, 265–267PubMedCrossRefGoogle Scholar
  77. 77.
    Maron, R, Zerubavel, R, Friedman, A and Cohen, IR (1983). T lymphocyte line specific for thyroglobulin produces or vaccinates against autoimmune thyroiditis in mice. J Immunol, 131, 2316–2322PubMedGoogle Scholar
  78. 78.
    Brahn, E and Trentham, DE (1987). Attenuation of collagen arthritis and modulation of delayed-type hypersensitivity by type II collagen reactive T-cell lines. Cell Immunol, 109, 139–147PubMedCrossRefGoogle Scholar
  79. 79.
    Kakimoto, K, Katsuki, M, Hirofuji, T et al. (1988). Isolation of T cell line capable of protecting mice against collagen-induced arthritis. J Immunol, 140, 78–83PubMedGoogle Scholar
  80. 80.
    Sano, S, Suda, T, Qian, J-H et al. (1987). Abrogation of the capacity of delayed-type hypersensitivity responses to alloantigens by intravenous injection of neuraminidase-treated allogeneic cells. J Immunol, 139, 3652–3659PubMedGoogle Scholar
  81. 81.
    Hahn, BH and Ebling, FM (1984). Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. J Immunol, 132, 187–190PubMedGoogle Scholar
  82. 82.
    Fritz, RB and Desjardins, AE (1982). Idiotypes of Lewis rat antibodies to encephalitogenic peptides of guinea pig myelin basic protein: in vitro and in vivo studies. J Immunol, 128, 247–250PubMedGoogle Scholar
  83. 83.
    Lennon, VA and Lambert, EHJ (1981). Monoclonal autoantibodies to acetyl choline receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity. Ann NY Acad Sci, 377, 77–96PubMedCrossRefGoogle Scholar
  84. 84.
    Hahn, BH and Ebling, FM (1983). Suppression of NZB/NZW murine nephritis by administration of a syngeneic monoclonal antibody to DNA: Possible role of anti-idiotypic antibodies. J Clin Invest, 71, 1728–1736PubMedCrossRefGoogle Scholar
  85. 85.
    Christadoss, P, Lennon, VA and David, C (1979). Genetic control of experimental autoimmune myasthenia gravis in mice: I. Lymphocyte proliferative response to acetylcholine receptor is under H-2-linked Ir gene control. J Immunol, 123, 2540–2543PubMedGoogle Scholar
  86. 86.
    De Baets, MC, Einarson, B, Lindstrom, JM and Weigle, WO (1982). Lymphocyte activation in experimental autoimmune myasthenia gravis. J Immunol, 128, 2228–2235PubMedGoogle Scholar
  87. 87.
    Krolick, KA and Urso, OE (1986). Influence of T cell specificity on the antibody response to the acetylcholine receptor. J Neuroimmunol, 13, 75–87PubMedCrossRefGoogle Scholar
  88. 88.
    Neilson, EG and Phillips, SM (1982). Suppression of interstitial nephritis by auto-anti-idiotypic immunity. J Exp Med, 155, 179–189PubMedCrossRefGoogle Scholar
  89. 89.
    Neilson, EG, McCafferty, E, Phillips, SM et al. (1984). Antiidiotypc immunity in interstitial nephritis. II. Rats developing anti-tubular basement membrane disease fail to make an antiidiotypic regulatory response: the modulatory role of an RT7.1+, OX8- suppressor T cell mechanism. J Exp Med, 159, 1009–1026PubMedCrossRefGoogle Scholar
  90. 90.
    Stamenkovic, I, Stegagno, M, Wright, KA et al. (1988). Clonal dominance among T lymphocyte infiltrates in arthritis. Proc Natl Acad Sci USA, 85, 1179–1183PubMedCrossRefGoogle Scholar
  91. 91.
    Butcher, EC (1986). The regulation of lymphocyte traffic. Curr Top Microbiol Immunol, 128, 85–122PubMedGoogle Scholar
  92. 92.
    Hamann, A, Jablonski-Westlich, D, Scholz, K-U et al. (1988). Regulation of lymphocyte homing. I. Alterations in homing receptor expression and organ-specific high endothelial venule binding of lymphocytes upon activation. J Immunol, 140, 737–743PubMedGoogle Scholar
  93. 93.
    Mountz, JD, Gause, WC, Finkelman, FD and Steinberg, AD (1988). Prevention of lymphadenopathy in MRL/lpr/lpr mice by blocking peripheral lymph node homing with Mel-14 in vivo. J Immunol, 140, 2943–2949PubMedGoogle Scholar
  94. 94.
    Kelley, VE, Gaulton, GN, Hattori, M et al. (1988). Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol, 140, 59–61PubMedGoogle Scholar
  95. 95.
    Kelley, VE, Gaulton, and Strom, TB (1987). Inhibitory effects of anti-interleukin 2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: the role of complement and epitope. J Immunol, 138, 2771–2775PubMedGoogle Scholar
  96. 96.
    Kumar, A, Moreau, J-L, Gibert, M and Thèze, J (1987). Internalization of interleukin 2 (IL-2) by high affinity IL-2 receptors is required for the growth of IL-2-dependent T cell lines. J Immunol, 139, 3680–3684PubMedGoogle Scholar
  97. 97.
    Murphy, JR, Bishai, W, Borowski, M et al (1986). Genetic construction expression and melanoma selective cytotoxicity of a diptheria toxin-related α-melanocyte-stimulating hormone fusion protein. Proc Natl Acad Sci USA, 83, 8258–8262PubMedCrossRefGoogle Scholar
  98. 98.
    Vitetta, ES and Uhr, JW (1985). Immunotoxins. Ann Rev Immunol, 3, 197–212CrossRefGoogle Scholar
  99. 99.
    Kelley, VE, Bacha, P, Pankewycz, O et al. (1988). Interleukin-2 toxin fusion protein abolishes cell mediated immunity in vivo. Proc Natl Acad Sci USA, 85, 3980–3984PubMedCrossRefGoogle Scholar
  100. 100.
    Kelley, VE, Naor, D, Tarcic, N et al. (1986). Anti-interleukin 2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens. J Immunol, 137, 2122–2124PubMedGoogle Scholar
  101. 101.
    Nepom, GT, Hansen, JA and Nepom, BS (1987). The molecular basis for HLA class II associations with rheumatoid arthritis. J Clin Immunol, 7, 1–7PubMedCrossRefGoogle Scholar
  102. 102.
    Warren, MK and Vogel, SN (1985). Opposing effects of glucocorticoids on interferon-γ-induced murine macrophage Fc receptor and Ia antigen expression. J Immunol, 134, 2462–2469PubMedGoogle Scholar
  103. 103.
    Collins, T, Korman, AJ, Wake, CT et al. (1984). Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA, 81, 4917–4921PubMedCrossRefGoogle Scholar
  104. 104.
    Fontana, A, Fierz, W and Wekerle, H (1984). Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature, 307, 273–276PubMedCrossRefGoogle Scholar
  105. 105.
    Fierz, W, Endler, B, Reske, K et al. (1985). Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol, 134, 3785–3793PubMedGoogle Scholar
  106. 106.
    Jacob, CO, van der Meide, PH and McDevitt, HO (1987). In vivo treatment of (NZB x NZW)F1 lupus-like nephritis with monoclonal antibody to 7-interferon. J Exp Med, 166, 798–803PubMedCrossRefGoogle Scholar
  107. 107.
    Remy, J-J, Salamero, J, Michel-Bechet, M and Charreire, J (1987). Experimental autoimmune thyroiditis induced by recombinant interferon-γ. Immunol Today, 8, 73CrossRefGoogle Scholar
  108. 108.
    Heremans, H, Dijkmans, R, Sobis, H et al. (1987). Regulation by interferons of the local inflammatory response to bacterial lipopolysaccharide. J Immunol, 138, 4175–4179PubMedGoogle Scholar
  109. 109.
    Billiau, A, Heremans, H, Vandekerckhove, F et al. (1988). Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J Immunol, 140, 1506–1510PubMedGoogle Scholar
  110. 110.
    Ottemess, IG and Chang, Y-H (1976). Comparative study of cyclophosphamide, 6-mercaptopurine, azathiaprine and methotrexate. Relative effects on the humoral and cellular immune response in the mouse. Clin Exp Immunol, 26, 346–354Google Scholar
  111. 111.
    Lombardino, JG and Otterness, IG (1981). Novel immunosuppressive agents. Potent immunological activity of some benzothiopyrano[4,3-c]pyrazol-3-ones. I Med Chem, 24, 830–834CrossRefGoogle Scholar
  112. 112.
    Ottemess, IG (1981). Comparative activity of CP-17,193 and five established immunosuppressives towards the antigens SRBC and EL4. Clin Exp Immunol, 46, 332–339Google Scholar
  113. 113.
    Otterness, IG and Bliven, ML (1984). Pharmacologic modulation of immune function: some considerations for design of drug therapy. Adv Inflam Res, 7, 185–199Google Scholar
  114. 114.
    Kino, T, Hatanaka, H, Hashimoto, N et al. (1987). FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot, 40, 1249–1255PubMedGoogle Scholar
  115. 115.
    Hess, AD and Tutschka, PJ (1980). Effect of CsA on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol, 124, 2601–2608PubMedGoogle Scholar
  116. 116.
    Andrus, L and Lafferty, KJ (1982). Inhibition of T cell activity by cyclosporin A. Scand I Immunol, 15, 449–458CrossRefGoogle Scholar
  117. 117.
    Krusemeier, M and Snow, EC (1988). Induction of lymphokine responsiveness of hapten-specific B lymphocytes promoted through an antigen-mediated T helper lymphocyte intereaction. J Immunol, 140, 367–375PubMedGoogle Scholar
  118. 118.
    Sideras, P, Funa, K, Zalcberg-Quintana, I et al. (1988). Analysis by in situ hybridization of cells expressing mRNA for interleukin 4 in the developing thymus and in peripheral lymphocytes from mice. Proc Natl Acad Sci USA, 85, 218–221PubMedCrossRefGoogle Scholar
  119. 119.
    Reem, GH, Cook, LA and Vilcek, J (1983). Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by CsA. Science, 221, 63–65PubMedCrossRefGoogle Scholar
  120. 120.
    Herold, KC, Lancki, DW, Moldwin, RL and Fitch, FW (1986). Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol, 136, 1315–1321PubMedGoogle Scholar
  121. 121.
    Palacios, R (1982). Mechanism of T cell activation: role and functional relationship of HLA-DR antigens and interleukins. Immunol Rev, 63, 73–110PubMedCrossRefGoogle Scholar
  122. 122.
    Lillehoj, HS, Malek, TR and Shevach, EM (1984). Differential effects of cyclosporin A on the expression of T and B lymphocyte activation antigens. J Immunol, 133, 244–250PubMedGoogle Scholar
  123. 123.
    Prince, HE and John, JK (1986). Cyclosporin inhibits the expression of receptors for interleukin 2 and transferrin on mitogen-activated human T lymphocytes. Immunol Invest, 15, 463–472PubMedCrossRefGoogle Scholar
  124. 124.
    Larsson, E-L (1980) Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol, 124, 2828–2833PubMedGoogle Scholar
  125. 125.
    Miyawaki, T, Yachie, A, Ohzeki, S et al. (1983). Cyclosporin A does not prevent expression of the Tac antigen, a probable TCGF receptor molecule on mitogen-stimulated T cells. I Immunol, 130, 2737–2742Google Scholar
  126. 126.
    Dos Reiss, GA and Shevach, EM (1982). Effect of cyclosporin A on T cell function in vitro: the mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell. J Immunol, 129, 2360–2367Google Scholar
  127. 127.
    Ryffel, B, Muller, S and Foxwell, BC (1987). Cyclosporin-A allows the expression of high-affinity interleukin-2 binding sites on anti-T-cell antibody activated human T lymphocytes. Trans Proc, 19, 1199–1201Google Scholar
  128. 128.
    Colombani, PM, Robb, A and Hess, AD (1985). Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes. Science, 228, 337–339PubMedCrossRefGoogle Scholar
  129. 129.
    Russell, DH, Kibler, DH, Matrisian, L, Larson, DF, Poulos, B and Magiin, BE (1985). Prolactin receptors on human T and B lymphocytes: antagonism or prolactin binding of cyclosporine. J Immunol, 134, 3027–3031PubMedGoogle Scholar
  130. 130.
    Larson, DF (1986). Mechanism of action: antagonism of the prolactin receptor. Prog Allergy, 38, 222–238PubMedGoogle Scholar
  131. 131.
    Fidelus, RK, Laughter, AH, Twomey, JJ et al. (1984). The effect of cylosporine on ornithine decarboxylase induction with mitogens, antigens and lymphokines. Transplantation, 37, 383–387PubMedCrossRefGoogle Scholar
  132. 132.
    Rosoff, PM and Terres, G (1986). Cyclosporin A inhibits CA2+ dependent stimulation of the Na+/H+ antiport in human T cells. J Cell Biol, 103, 457–463PubMedCrossRefGoogle Scholar
  133. 133.
    Handschumacher, RE, Harding, MW, Rice, J et al. (1984). Ctyclophilin: a specific cytosolic binding protein for cyclosporin A. Science, 226, 544–547PubMedCrossRefGoogle Scholar
  134. 134.
    Borel, JF and Gunn, HC (1986). Cyclosporine as a new approach to therapy of autoimmune diseases. Ann NY Acad Sci, 475, 307–309PubMedCrossRefGoogle Scholar
  135. 135.
    Mountz, JD, Smith, HR, Wilder, RL et al. (1988). Cs-A therapy in MRL-lpr/lpr mice: amerlioration of immunopathology despite autoantibody production. J Immunol, 138, 157–163Google Scholar
  136. 136.
    Gunn, HC and Ryffel, B (1986). Successful treatment of autoimmunity in (NZB x NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. reduction of glomerulonephritis. Clin Exp Immunol, 64, 234–242PubMedGoogle Scholar
  137. 137.
    Jones, MG and Harris, G (1985). Prolongation of life in female NZB/NZW (F1) hybrid mice by cyclosporin A. Clin Exp Immunol, 59, 1–9PubMedGoogle Scholar
  138. 138.
    Gunn, HC (1986). Successful treatment of autoimmunity in (NZB x NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. reduction of autoantibodies. Clin Exp Immunol, 64, 225–233PubMedGoogle Scholar
  139. 139.
    Laupacis, N, Gardell, C, Dupre, J et al. (1983). Cyclosporin prevents diabetes in BB Wistar rats. Lancet, i, 10–12CrossRefGoogle Scholar
  140. 140.
    Borel, JF, Fewer, C, Gubler, HU and Stahelin, H (1976). Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions, 6, 468–475PubMedCrossRefGoogle Scholar
  141. 141.
    Kaibara, N, Hotokebuchi, T, Takagishi, K et al. (1984). Pathogenetic difference between collagen arthritis and adjuvant arthritis. J Expt Med, 159, 1388–1396CrossRefGoogle Scholar
  142. 142.
    Yocum, DE, Allen, JB, Wahl, SM et al. (1986). Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. Arthitis Rheum, 29, 262–273CrossRefGoogle Scholar
  143. 143.
    Nussenblatt, RB, Rodrigues, MM, Salinas-Carmona, MC et al. (1982). Modulation of experimental autoimmune uveitis with cyclosporin A. Arch Ophthal, 100, 1146–1149PubMedGoogle Scholar
  144. 144.
    Bolton, C, Borel, JF, Cuzner, ML et al. (1982). Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis. J Neurol Sci, 56, 147–153PubMedCrossRefGoogle Scholar
  145. 145.
    Schuller-Levis, GB, Kozlowski, PB and Wisniewski, HM (1986). Cyclosporin A treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis. Clin Immunol Immunopathol, 40, 244–252PubMedCrossRefGoogle Scholar
  146. 146.
    Takagishi, K, Kaibara, N, Hotokebuchi, T et al. (1986). Effects of cyclosporin on collagen induced arthritis in mice. Ann Rheum Dis, 45, 339–344PubMedCrossRefGoogle Scholar
  147. 147.
    Kaibara, N, Hotokebuchi, T, Takagishi, K and Katsuki, I (1983). Paradoxical effects of cyclosporin A on collagen arthritis in rats. J Exp Med, 158, 2007–2015PubMedCrossRefGoogle Scholar
  148. 148.
    Wiesinger, D and Borel, JF (1980). Studies on the mechanism of action of cyclosporin A. Immunobiology, 156, 454–463PubMedGoogle Scholar
  149. 149.
    Leapman, SB, Filo, RS, Smith, EJ and Smith, PG (1980). In vitro effects of cyclosporin A on lymphocyte subpopulations. I. Suppressor cell sparing by cyclosporin A. Transplantation, 30, 404–408PubMedCrossRefGoogle Scholar
  150. 150.
    Kupiec-Weglinski, JW, Filho, MA, Strom, TB and Tilney, NL (1984). Sparing of suppressor cells: a critical action of cyclosporine. Transplantation, 38, 97–101PubMedCrossRefGoogle Scholar
  151. 151.
    Kino, T, Hatanaka, H, Miyata, S et al. (1987). FK-506, a novel immunosuppressant isolated froma Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot, 40, 1256–1265PubMedGoogle Scholar
  152. 152.
    Inamura, N, Nakahara, K, Kino, T et al. (1988). Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK-506. Transplantation, 45, 206–209PubMedCrossRefGoogle Scholar
  153. 153.
    Ochiai, T, Nakajima, K, Nagata, M et al. (1987). Studies of the induction and maintenance of long-term graft acceptance by treatment with FK-506 in heterotopic cardiac allotransplantation in rats. Transplantation, 44, 734–733PubMedCrossRefGoogle Scholar
  154. 154.
    Ochiai, T, Nagata, M, Nakajima, K et al. (1987). Studies of the effects of FK-506 on renal allografting in the beagle dog. Transplantation, 44, 729–733PubMedCrossRefGoogle Scholar
  155. 155.
    Inamura, N, Hashimoto, M, Nakahara, K et al. (1988). Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol, 46, 82–90PubMedCrossRefGoogle Scholar
  156. 156.
    Sawada, S, Suzuki, G, Kawase, Y and Takaku, F (1987). Novel immunosuppressive agent, FK-506. In vitro effects on the cloned T cell activation. J Immunol, 139, 1797–1803PubMedGoogle Scholar
  157. 157.
    Cosimi, AB (1983). The clinical usefulness of antilymphocyte antibodies. Transplant Proc, 15, 583–589Google Scholar
  158. 158.
    Glass, NR, Miller, DT, Sollinger, HW and Beizer, FO (1983). A comparative study of steroids and heterologous antiserum in the treatment of renal allograft rejection. Transplant Proc, 15, 617–621Google Scholar
  159. 159.
    Russell, PS, Colvin, RB and Cosimi, AB (1984). Monoclonal antibodies for the diagnosis and treatment of transplant rejection. Annu Rev Med, 35, 63–79PubMedCrossRefGoogle Scholar
  160. 160.
    Ortho Multicenter Transplant Study Group (1985). A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med, 313, 337–342CrossRefGoogle Scholar
  161. 161.
    Gordon, RD, Starzl, TE, Fung, JJ et al. (1987). Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants. Nephron, 46,suppl. I, 56–59PubMedCrossRefGoogle Scholar
  162. 162.
    Gordon, RD, Tzakis, AG, Iwatsuki, S et al. (1988). Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation. Am J Kid Dis, 11, 141–144PubMedGoogle Scholar
  163. 163.
    Chatenoud, L, Jonker, M, Villemain, F et al. (1986). The human response to the OKT3 monoclonal antibody is oligoclonal. Science, 232, 1406–1408PubMedCrossRefGoogle Scholar
  164. 164.
    Shield, CF, Norman, DJ, Marlett, P et al. (1987). Comparison of antimouse and anti-horse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin. Nephron, 46,Suppl. 1, 48–51PubMedCrossRefGoogle Scholar
  165. 165.
    Cosimi, AB, Burton, RC and Kung, PC (1981). Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses. Transplant Proc, 13, 499PubMedGoogle Scholar
  166. 166.
    Wegelius, O, Laine, V, Lindstrom, B and Klockars, M (1970). Fistula of the thoracic duct as immunosuppressive treatment in rheumatoid arthritis. Acta Med Scand, 187, 539–544PubMedCrossRefGoogle Scholar
  167. 167.
    Cosimi, AB, Colvin, RB, Burton, RC et al. (1981). Use of monoclonal antibodies to T-cell subsets for immunological monitoring and treatment in recipients of renal allografts. N Engl J Med, 305, 308–314PubMedCrossRefGoogle Scholar
  168. 168.
    Bell, JD, Marshall, GD, Shaw, BA et al. (1983). Alterations in human thoracic duct lymphocytes during thoracic duct drainage. Transplant Proc, 15, 677–680Google Scholar
  169. 169.
    Obert, HJ and Hofschneider, PH (1985). Interferon bei chronischer Polyarthritis. Dtsch Med Wochenschr, 100, 1766–1769CrossRefGoogle Scholar
  170. 170.
    Schindler, J, Kennedy, SM and Wolfe, F (1988). Potential of gamma interferon in rheumatoid arthritis. In: Advances in Inflammation Research, Vol. 12, ed A Lewis, N Ackerman and I Otterness (New York: Raven Press), pp. 305–311Google Scholar
  171. 171.
    Seitz, M, Manz, G and Franke, M (1986). Einsatz von rekombinatem Human-Interferon Gamma bei Patienten mit rheumatoider Arthritis. Z Rheumatol, 45, 93–99PubMedGoogle Scholar
  172. 172.
    Lemmel, EM, Franke, M, Gaus, W et al. (1987). Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int, 7, 127–132PubMedCrossRefGoogle Scholar
  173. 173.
    Lemmel, E-M, Obert, HJ and Hofschneider, PH (1988). Low-dose gamma interferon in treatment of rheumatoid arthritis. Lancet, i, 598CrossRefGoogle Scholar
  174. 174.
    Tosato, G, Steinberg, A and Blaese, RM (1981). Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med, 305, 1238–1243PubMedCrossRefGoogle Scholar
  175. 175.
    Lotz, M, Tsoukas, CD, Fong, S et al. (1985). Regulation of Epstein-Barr virus infection by recombinant interferon. Selected sensitivity to IFN-gamma. Eur J Immunol, 15, 520–525PubMedCrossRefGoogle Scholar
  176. 176.
    Panitch, HS, Haley, AS, Hirsch, RL and Johnson, KP (1986). A trial of gamma interferon in multiple sclerosis: clinical results. Neurology, 36,Suppl. 1, 285Google Scholar
  177. 177.
    Shidani, B, Colle, JH, Motta, I and Truffa-Bachi, P (1983). Effect of cyclosporin A on the induction and activation of B memory cells by thymus-independent antigens in mice. Eur J Immunol, 13, 359–363PubMedCrossRefGoogle Scholar
  178. 178.
    Tosato, G, Pike, SE, Koski, IR and Blaese, RM (1982). Selective inhibition of immunoregulatory cell function by cyclosporin A. J Immunol, 128, 1986–1991PubMedGoogle Scholar
  179. 179.
    Wang, BS, Heacock, EH, Collins, KH et al. (1981). Suppressive effects of cyclosporin A on the induction of alloreactivity in vitro and in vivo. J Immunol, 127, 89–93PubMedGoogle Scholar
  180. 180.
    Weil, C (1984). Cyclosporin A: review of results in organ and bone-marrow transplantation in man. Med Res Rev, 4, 221–265PubMedCrossRefGoogle Scholar
  181. 181.
    O’Connor, GR (1982). Epidemiology and pathogenesis of the ocular and cerebral forms of Behçet’s disease. Behçet’s Disease, ed. G Inaba (Tokyo: University of Tokyo Press), pp. 115–126Google Scholar
  182. 182.
    Nussenblatt, RB, Gery, I, Ballintine, EJ and Wacker, WB (1980). Cellular responsiveness of uveitis patients to retinal S-antigen. Am J Ophthalmol, 89, 173–179PubMedGoogle Scholar
  183. 183.
    Ohno, S (1981). Voght-Koyanagi, and Harada’s diseases. Trans Ophthalmol Soc UK, 101, 335–341PubMedGoogle Scholar
  184. 184.
    Sakane, T, Kotani, H, Takada, S and Tsunematsu, T (1982). Functional aberration of T cell subsets in patients with Behçet’s disease. Arthritis Rheum, 25, 1343–1351PubMedCrossRefGoogle Scholar
  185. 185.
    Bottazzo, GF, Florin-Christensen, A and Doniach, D (1974). Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet, ii, 1279–1283CrossRefGoogle Scholar
  186. 186.
    MacCuish, AC and Irvine, WJ (1975). Autoimmunological aspects of diabetes mellitus. Clin Endocrinol, 4, 435–471CrossRefGoogle Scholar
  187. 187.
    Nerup, J, Andersen, OO, Bendixen, G et al. (1974). Cell-mediated immunity in diabetes mellitus. Proc R Soc Med, 67, 506–513PubMedGoogle Scholar
  188. 188.
    Assan, R, Debray-Sachs, M, Laborie, C et al. (1985). Metabolic and immunological effects of cyclosporin in recently diagnosed type I diabetes mellitus. Lancet, i, 67–71CrossRefGoogle Scholar
  189. 189.
    Stiller, CR, Dupré, J, Gent, M et al. (1984). Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science, 223, 1362–1367PubMedCrossRefGoogle Scholar
  190. 190.
    Allison, MC and Pounder, RE (1984). Cyclosporin for Crohn’s disease. Lancet, i, 902–903CrossRefGoogle Scholar
  191. 191.
    Bianchi, PA, Mondelli, M, Quatro di Palo, F and Ranzi, T (1984). Cyclosporin for Chrohn’s disease. Lancet, i, 1242CrossRefGoogle Scholar
  192. 192.
    Gupta, S, Keshavarzian, A and Hodgson, HJF (1984). Cyclosporin in ulcerative colitis. Lancet, ii, 1277–1278CrossRefGoogle Scholar
  193. 193.
    Thivolet, J, Barthelemy, H, Rigot-Muller, G and Bendelac, A (1985). Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet, i, 334–335CrossRefGoogle Scholar
  194. 194.
    Isenberg, DA, Snaith, ML, Morrow, WJW et al. (1981). Cyclosporin A for the treatment of systemic lupus erythematosus. Int I Immunopharmacol, 3, 163–169CrossRefGoogle Scholar
  195. 195.
    Miescher, PA and Miescher, A (1985). Combined Ciclosporin steroid treatment of systemic lupus erythematosus. In Ciclosporin in Autoimmune Diseases, ed. R Schindler, (Berlin: Springer Verlag), pp. 337–345Google Scholar
  196. 196.
    Feutren, G, Querin, S, Chatenoud, L, Noel, LH et al. (1985). The effects of Ciclosporin in twelve patients with severe systemic lupus. In Ciclosporin in Autoimmune Diseases, ed. R Schindler, (Berlin: Springer Verlag), pp. 366–372Google Scholar
  197. 197.
    van Rijthoven, AWAM, Dijkmans, BAC, Goei The, HS et al. (1986). Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis, 45, 726–731PubMedCrossRefGoogle Scholar
  198. 198.
    Forre, O, Bjerkhoel, F, Salvesen, CF et al. (1987). An open, controlled, randomized comparison of cyclosporin and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum, 30, 88–92PubMedCrossRefGoogle Scholar
  199. 199.
    Weinblatt, ME, Coblyn, JS, Fraser, PA et al. (1987). Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum, 30, 11–17PubMedCrossRefGoogle Scholar
  200. 200.
    Dougados, M and Amor, B (1987). Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial. Arthritis Rheum, 30, 83–87PubMedCrossRefGoogle Scholar
  201. 201.
    Bliven, ML, Cunningham, AC and Otterness, IG (1988). A pharmacological study of the relationship between lymphocyte function and surface antigen expression. Agents Actions, 25 Google Scholar
  202. 202.
    Chapman, JR, Griffiths, D, Harding, NGL and Morris, PJ (1985). Reversibility of cyclosporin nephrotoxicity after three months’ treatment. Lancet, i, 128–129CrossRefGoogle Scholar
  203. 203.
    von Graffenried, B and Harrison, WB (1985). Renal function in patients with autoimmune diseases treated with cyclosporine. Transplant Proc, 17,Suppl. 1, 215–231Google Scholar
  204. 204.
    Dijkmans, BAC, van Rijthoven, AWAM, Goei The, HS et al. (1987). Effects of cyclosporin on serum creatinine in patients with rheumatoid arthritis. Eur J Clin Pharmacol, 31, 541–545PubMedCrossRefGoogle Scholar
  205. 205.
    Bird, HA, Yu, H and Cooper, EH (1984). Renal proximal dysfunction in rheumatic diseases. Br Med J, 288, 1044–1045CrossRefGoogle Scholar
  206. 206.
    Berg, KJ, Forre, O, Bjerkhoel, F et al. (1986). Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int, 29, 1180–1187PubMedCrossRefGoogle Scholar
  207. 207.
    Breedveld, FC, Valentijn, RM, Westedt, ML and Weening, J (1985). Rapidly progressive glomerulonephritis with glomerular crescent formation in rheumatoid arthritis. Clin Rheumatol, 4, 353–359PubMedCrossRefGoogle Scholar
  208. 208.
    Kimberly, RP, Bowden, RE, Keiser, HR and Plotz, PH (1978). Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med, 64, 804–807PubMedCrossRefGoogle Scholar
  209. 209.
    Wegmueller, E (1985). Nicht-steroidale Antirheumatika und Nephrotoxizitat. Dtsch Med Wochenschr, 110, 469–472CrossRefGoogle Scholar
  210. 210.
    Hiestand, PC, Gunn, HC, Gale, JM et al. (1985). Comparison of the pharmacological profiles of cyclosporine, (Nva2)-cyclosporine and (Val2)dihydro-cyclosporine. Immunology, 55, 249–255PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Ivan G. Otterness
    • 1
  • Marcia L. Bliven
    • 1
  1. 1.Department of Immunology and Infectious DiseasesPfizer Central ResearchGrotonUSA

Personalised recommendations